• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
OB
CMECNE

Mild Cerebral Ventriculomegaly on Prenatal Ultrasound – Next Steps and Clinical Implications

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Define mild ventriculomegaly
2. Describe the management of a pregnancy when mild ventriculomegay is identified

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Jan 25 2022 through Jan 25 2024, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

CLINICAL ACTIONS:

According to SMFM recommendations, mild cerebral ventriculomegaly is identified on a prenatal ultrasound report when the atrium measures between 10-12 mm.  Next steps include

  • Detailed anatomical study
  • Refer for genetic counseling
  • Consider diagnostic testing for aneuploidy
    • ACOG/SMFM  guidance recommends offering invasive testing using microarray in the setting of fetal structural anomalies seen on prenatal ultrasound
  • Consider maternal toxoplasmosis and cytomegalovirus (CMV) testing regardless of whether the patient is aware of previous exposure
  • Consider fetal MRI for detection of associated cortical anomalies or signs of cerebral infection
    • May be of less value if a patient has already had an ultrasound examination by a professional with expertise in fetal brain imaging on ultrasound
  • Deliver based on standard clinical indications
  • If no abnormal findings detected on thorough examination, prognosis is favorable and the newborn is expected to be normal
  • Repeat ultrasound in the 3rd trimester, (30-34 weeks gestation)
    • Prognosis is better if measurement remains stable or improves/resolves
    • Serial ultrasounds unlikely to be helpful
  • Antepartum fetal testing not likely to be beneficial
  • Antiplatelet antibodies if intracranial hemorrhage also present

SYNOPSIS:

Mild/moderate ventriculomegaly may be seen in approximately 1% of fetuses. While mild cerebral ventriculomegaly may resolve or be of no consequence, clinical work-up is required to determine whether there is any physical obstruction, decreased cerebral volume or conditions that may alter production, reabsorption or cerebral spinal fluid (CSF) flow within the cerebral ventricles.  Measurements of the lateral cerebral ventricles are obtained from an axial plane at the level of the thalamic nuclei.

KEY POINTS:

  • ‘Fetal cerebral ventriculomegaly’ is present if the atrial diameter is ≥10mm and the SMFM further refines this definition as follows
    • Mild: 10-12 mm
    • Moderate: 13-15 mm
    • Severe: >15 mm
  • Ventriculomegaly is found in 0.15%-0.7% of chromosomally normal/euploid fetuses
  • When isolated, the incidence of an abnormal karyotype is 3.8% although some centers report higher rates
  • If patient opts for invasive testing, microarray is critical as copy number variants (CNVs) have been found in 8.3% of isolated cases following normal karyotype and were highly correlated with neurodevelopmental disorders
  • Ventriculomegaly is also associated with genetic syndromes, brain malformations, feto-neonatal alloimmune thrombocytopenia and congenital infections
    • Often, no cause will be found
  • Postnatal follow-up by pediatric neurologists and specialists should be considered
    • While children with a prenatal diagnosis of mild ventriculomegaly will overall have a very good prognosis, a few may still have abnormal neurodevelopment, dependent on associated anomalies and etiology
  • When only one ventricle is mildly enlarged and there are no other findings, chromosomal work up is more likely to be normal
    • There is still a risk of congenital infections (8.2%) and additional brain abnormalities (5% prenatal and 6.4% postnatal), as well as a risk of neurodevelopmental delay of 5.9%

Learn More – Primary Sources:

Mild fetal cerebral ventriculomegaly: prevalence, characteristics, and utility of ancillary testing in cases presenting to a tertiary referral center

Copy Number Variations with Isolated Fetal Ventriculomegaly

ACOG Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders

ACOG Practice Bulletin No. 226: Screening for Fetal Chromosomal Abnormalities

Society for Maternal-Fetal Medicine (SMFM) Consult Series #45: Mild fetal ventriculomegaly: Diagnosis, evaluation, and management

Fetal Mild Ventriculomegaly: Still a Challenging Problem

Perinatal and Long-term Outcome in Fetuses Diagnosed With Isolated Unilateral Ventriculomegaly: Systematic Review and Meta-analysis

Locate a genetic counselor or genetics services:

Genetic Services Locator-ACMG

Genetic Services Locator-NSGC

Genetic Services Locator-CAGC

Take a post-test and get CME credits

TAKE THE POST TEST

2nd Trimester Ultrasound Reference Library, Now Available on Your Phone with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite

< Previous
All OB Posts
Next >

Related ObG Topics:

Genetic Counseling: Who to Refer and What They Should Expect
Is There Benefit to Prenatal Ultrasound Between 35 and 37 Weeks?
Are Copy Number Variants Associated with Soft Markers?
Practical obstetrics info for your women's healthcare practice

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site